Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Lenvatinib + Pembrolizumab for Anal Cancer
Recruiting1 awardPhase 2
Chicago, Illinois
"This trial aims to see if combining lenvatinib with pembrolizumab is safe and effective for treating anal/rectal cancer that has spread and is not responding to standard treatment."
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service